REGULUS THERAPEUTICS

Our technology is based on our position as exclusive licensee of IP provided by Alnylam and Ionis, two leaders in oligonucleotide-based therapeutics, along with our continued novel discoveries since inception... Regulus aims to develop important, novel oligonucleotide therapeutics that are designed to inhibit dysregulated micro RNA targets for the benefit of patients with genetically based orphan diseases. We are focused on orphan kidney diseases where micro RNA genetic drivers are implicated and there are clear unmet medical needs with an initial focus on orphan kidney diseases, including Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Also known as: Regulus Therapeutics Inc.

Primary location: San Diego United States